ResearcherNanjing Drum Tower HospitalActive in the last 2 years
Linxi Zhu
Matched on OpenAlex author ID A5082404382. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 17
2022: 2 papers · 2023: none · 2024: 1 paper · 2025: 1 paper
Papers 4
- SP1-Mediated Glycolytic Reprogramming Promotes Tumorigenesis and Progression in Pancreatic Cancer. Co-author DOI 10.1002/advs.202510071↗
- Loss of Claudin-1 incurred by DNMT aberration promotes pancreatic cancer progression. Co-author DOI 10.1016/j.canlet.2024.216611↗
- Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclitaxel, gemcitabine, and concurrent radiot… Co-author DOI 10.3389/fonc.2022.879661↗
- Case Report: Pathologic Complete Response to Induction Therapy in a Patient With Potentially Resectable Pancreatic Cancer. Co-author DOI 10.3389/fonc.2022.898119↗
Closest collaborators
The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yudong Qiu · 4 shared papers, 2022–2025 · strength 0.64
- Paper Loss of Claudin-1 incurred by DNMT aberration promotes pancreatic cancer progression. DOI 10.1016/j.canlet.2024.216611↗
- Paper SP1-Mediated Glycolytic Reprogramming Promotes Tumorigenesis and Progression in Pancreatic Cancer. DOI 10.1002/advs.202510071↗
- Paper Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclit… DOI 10.3389/fonc.2022.879661↗
- Qi Li · 3 shared papers, 2022–2025 · strength 0.43
- Paper SP1-Mediated Glycolytic Reprogramming Promotes Tumorigenesis and Progression in Pancreatic Cancer. DOI 10.1002/advs.202510071↗
- Paper Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclit… DOI 10.3389/fonc.2022.879661↗
- Paper Case Report: Pathologic Complete Response to Induction Therapy in a Patient With Potentially Resectable Pancreatic Canc… DOI 10.3389/fonc.2022.898119↗
- Neng Tang · 2 shared papers, 2024–2025 · strength 0.40
- Hexing Hang · 2 shared papers, 2024–2025 · strength 0.40
- Hao Cheng · 2 shared papers, 2022–2025 · strength 0.31
- Changchang Lu · 2 shared papers, 2022 · strength 0.25
- Paper Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclit… DOI 10.3389/fonc.2022.879661↗
- Paper Case Report: Pathologic Complete Response to Induction Therapy in a Patient With Potentially Resectable Pancreatic Canc… DOI 10.3389/fonc.2022.898119↗
- Lei Wang · 2 shared papers, 2022 · strength 0.25
- Paper Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclit… DOI 10.3389/fonc.2022.879661↗
- Paper Case Report: Pathologic Complete Response to Induction Therapy in a Patient With Potentially Resectable Pancreatic Canc… DOI 10.3389/fonc.2022.898119↗
- Xin Qiu · 2 shared papers, 2022 · strength 0.25
- Paper Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclit… DOI 10.3389/fonc.2022.879661↗
- Paper Case Report: Pathologic Complete Response to Induction Therapy in a Patient With Potentially Resectable Pancreatic Canc… DOI 10.3389/fonc.2022.898119↗
- Juan Du · 2 shared papers, 2022 · strength 0.25
- Paper Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclit… DOI 10.3389/fonc.2022.879661↗
- Paper Case Report: Pathologic Complete Response to Induction Therapy in a Patient With Potentially Resectable Pancreatic Canc… DOI 10.3389/fonc.2022.898119↗
- Jun Chen · 2 shared papers, 2022 · strength 0.25
- Paper Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclit… DOI 10.3389/fonc.2022.879661↗
- Paper Case Report: Pathologic Complete Response to Induction Therapy in a Patient With Potentially Resectable Pancreatic Canc… DOI 10.3389/fonc.2022.898119↗
- Baorui Liu · 2 shared papers, 2022 · strength 0.25
- Paper Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclit… DOI 10.3389/fonc.2022.879661↗
- Paper Case Report: Pathologic Complete Response to Induction Therapy in a Patient With Potentially Resectable Pancreatic Canc… DOI 10.3389/fonc.2022.898119↗
- Wangsen Cao · 1 shared paper, 2024 · strength 0.21
- Jiatong Tang · 1 shared paper, 2025 · strength 0.19
- Chao Yan · 1 shared paper, 2025 · strength 0.19
- Xiao Fu · 1 shared paper, 2025 · strength 0.19
- Zhenghua Cai · 1 shared paper, 2025 · strength 0.19
- Ju Dong Yang · 1 shared paper, 2022 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.